• We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate. Neither her serum nor bone aluminum concentrations indicated aluminum toxicity. However, the presence of a positive deferoxamine-infusion test was suggestive of an elevated body burden of aluminum. Treatment with deferoxamine resulted in marked clinical improvement in her neurologic status within two months. The utility of using the deferoxamineinfusion test rather than serum aluminum levels in evaluating aluminum toxicity in chronic renal failure is suggested.
(Arch Intern Med 1986;146:2063-2064)
Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM. Encephalopathy in Chronic Renal Failure Responsive to Deferoxamine Therapy: Another Manifestation of Aluminum Neurotoxicity. Arch Intern Med. 1986;146(10):2063–2064. doi:10.1001/archinte.1986.00360220245039
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.